NDA 210828 · Uihc Pet Imaging
Gallium Ga 68 Edotreotide
Gallium Ga-68 Edotreotide · Intravenous
NovelOrphanLast checked: Nov 19, 2026Latest source record: Jul 27, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Aug 21, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
19
1 Phase 3, 6 recruiting
FAERS reports
7
2 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 8, 2021.
Ga 68 DOTATOC Injection is indicated for use with positron emission tomography (PET) for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients. Ga 68 DOTATOC Injection is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients. ( 1 )
Mechanism: Ga 68 DOTATOC binds to somatostatin receptors, with highest affinity (K i = 2.5± 0.5 nanomolar) for subtype 2 receptors (sstr2). Ga 68 DOTATOC binds to cells that express somatostatin receptors including malignant neuroendocrine cells, which overexpress sstr2 receptors. Gallium 68 is a β+ emitting radionuclide with associated 511 keV annihilation photons that allow positron emission tomography (PET) imaging.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- GALLIUM GA 68 EDOTREOTIDE · GALLIUM GA-68 EDOTREOTIDE 0.5-4mCi/ML · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Gallium Ga-68 Edotreotide" as an intervention, any sponsor and status, largest first.
University of California, San FranciscoAcademic, hospital or other
NCT02177773 · 300 participants · Start Jun 23, 2014 · Primary completion Aug 7, 2017
Drug: Gallium Ga 68-Edotreotide · For: Neuroendocrine Tumor; Paraganglioma; Carcinoid Tumors and 1 more
Sites: San Francisco, California
Sue O'DorisioAcademic, hospital or other
NCT01619865 · 223 participants · Start Feb 21, 2012 · Primary completion Aug 27, 2017
Drug: 68Ga-DOTATOC PET/CT · For: Neuroendocrine Tumors; Carcinoid Tumors; Neuroblastoma and 1 more
Sites: Iowa City, Iowa
Sue O'DorisioAcademic, hospital or other
NCT02441062 · 122 participants · Start Sep 2015 · Primary completion Jan 20, 2020
Drug: 68Ga-DOTATOC PET/CT · For: Neuroendocrine Tumors; Carcinoid Tumors; Neuroblastoma and 1 more
Sites: Iowa City, Iowa
Vastra Gotaland RegionGovernment (non-federal)
NCT04206163 · 78 participants · Start Jan 20, 2020 · Primary completion Jun 24, 2024
Drug: Blood sample · For: Acute Myocarditis; Cardiac Sarcoidosis
Sites: Gothenburg, Sweden
Sue O'DorisioAcademic, hospital or other
NCT01869725 · 68 participants · Start Apr 1, 2013 · Primary completion Dec 26, 2018
Drug: gallium Ga 68-edotreotide · For: Adult Medulloblastoma; Childhood Medulloblastoma; Neuroblastoma and 2 more
Sites: Iowa City, Iowa
Mayo ClinicAcademic, hospital or other
NCT04082520 · 42 participants (planned) · Start Apr 14, 2020 · Primary completion Sep 4, 2027
Drug: Lutetium Lu 177 Dotatate · For: Grade 1 Meningioma; Grade 2 Meningioma; Grade 3 Meningioma and 2 more
Sites: Rochester, Minnesota
National Cancer Institute (NCI)NIH
NCT05691465 · 35 participants (planned) · Start Dec 27, 2023 · Primary completion Jun 1, 2027
Drug: Lutetium Lu 177 Dotatate · For: Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Neuroendocrine Carcinoma and 1 more
Sites: Duarte, California; Los Angeles, California; Sacramento, California · 13 sites in all
Joshua PalmerAcademic, hospital or other
NCT07150806 · 30 participants (planned) · Start Nov 12, 2025 · Primary completion Dec 31, 2026
Drug: Actinium Ac 225 DOTATATE RYZ101; L-lysine/L-arginine-containing Amino Acid · For: Recurrent Meningioma
Sites: Columbus, Ohio
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- potentiating drug interaction5
- extravasation1
- hypokalaemia1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2025 | 6 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Uihc Pet Imaging
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.